Addition of rituximab significantly improves outcomes in patients with diffuse large B-cell lymphoma a single-center, retrospective study

Abstract

CHOP chemotherapy has been used as a standard first-line treatment for diffuse large B-cell lymphoma since the 1970s. Phase III trials have shown that the addition of rituximab to CHOP chemotherapy leads to significant improvements in response rate, progression-free survival and overall survival.